iRadimed (IRMD)
(Delayed Data from NSDQ)
$47.98 USD
-1.25 (-2.54%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $47.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Income Statements
Fiscal Year end for iRadimed Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 66 | 53 | 42 | 32 | 39 |
Cost Of Goods | 15 | 12 | 10 | 8 | 9 |
Gross Profit | 50 | 41 | 32 | 24 | 30 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 26 | 22 | 24 | 21 |
Income After Depreciation & Amortization | 20 | 16 | 10 | -1 | 9 |
Non-Operating Income | 2 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 22 | 16 | 10 | -1 | 9 |
Income Taxes | 5 | 3 | 1 | -2 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 17 | 13 | 9 | 1 | 10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 17 | 13 | 9 | 1 | 10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 21 | 16 | 11 | 1 | 10 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | 20 | 16 | 10 | -1 | 9 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 12.72 | 12.64 | 12.59 | 12.44 | 12.28 |
Diluted EPS Before Non-Recurring Items | 1.35 | 1.02 | 0.74 | 0.11 | 0.78 |
Diluted Net EPS (GAAP) | 1.35 | 1.02 | 0.74 | 0.11 | 0.78 |
Fiscal Year end for iRadimed Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 17.93 | 17.60 | 17.45 | 16.50 | 16.13 |
Cost Of Goods | 3.92 | 4.21 | 4.04 | 3.67 | 3.94 |
Gross Profit | 14.01 | 13.39 | 13.41 | 12.84 | 12.19 |
SG&A, R&D, and Dept/Amort Expenses | 8.38 | 8.64 | 8.25 | 6.93 | 7.22 |
Income After SG&A, R&D, and Dept/Amort Expenses | 5.63 | 4.75 | 5.16 | 5.91 | 4.97 |
Non-Operating Income | 0.64 | 0.50 | 0.52 | 0.50 | 0.34 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 6.27 | 5.24 | 5.68 | 6.41 | 5.30 |
Income Taxes | 1.37 | 1.11 | 1.14 | 1.34 | 1.12 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 4.90 | 4.14 | 4.54 | 5.07 | 4.18 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 4.90 | 4.14 | 4.54 | 5.07 | 4.18 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 12.76 | 12.75 | 12.74 | 12.74 | 12.72 |
Diluted EPS Before Non-Recurring Items | 0.38 | 0.32 | 0.36 | 0.40 | 0.33 |
Diluted Net EPS (GAAP) | 0.38 | 0.32 | 0.35 | 0.40 | 0.33 |